Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lygen-V is an oral multivitamin and nutritional supplement developed and marketed by Healthcare Pharmaceuticals Ltd., a pharmaceutical company based in Bangladesh. The product is formulated as a tablet containing a combination of essential vitamins (A, D3, E, C, B1, B2, B6, B12, Nicotinamide, and Folic Acid) and the amino acid L-lysine. It is indicated for nutritional supplementation and the prevention of vitamin deficiencies in both children and adults. The inclusion of L-lysine is intended to improve appetite, promote growth in height and weight, support muscle protein synthesis, and aid in calcium absorption. As a nutritional supplement, Lygen-V functions by providing micronutrients that serve as essential cofactors for various metabolic processes and physiological functions, rather than acting on a specific molecular pharmacologic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on multivitamin + l-lysine.